Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19

Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are being deployed, but the global need greatly exceeds the supply, and different formulations might be required for specific populations. Here we report Day 42 interim safety and immunogenicity data from an observer-blind...

Descripción completa

Detalles Bibliográficos
Autores principales: Ward, Brian J., Gobeil, Philipe, Séguin, Annie, Atkins, Judith, Boulay, Iohann, Charbonneau, Pierre-Yves, Couture, Manon, D’Aoust, Marc-André, Dhaliwall, Jiwanjeet, Finkle, Carolyn, Hager, Karen, Mahmood, Asif, Makarkov, Alexander, Cheng, Matthew P., Pillet, Stéphane, Schimke, Patricia, St-Martin, Sylvie, Trépanier, Sonia, Landry, Nathalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205852/
https://www.ncbi.nlm.nih.gov/pubmed/34007070
http://dx.doi.org/10.1038/s41591-021-01370-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205852/
https://www.ncbi.nlm.nih.gov/pubmed/34007070
http://dx.doi.org/10.1038/s41591-021-01370-1

Ejemplares similares